Skip to content
Recall Observatory FDA recall evidence

Device product

Custom procedural convenience kits and trays, general hospital use, labeled as: a) Baby PICC Kit, kit number UIBP90J; b) Baby PICC Kit, kit number UIBP90K; c) PORT PACK (PS 058330), kit number UIPO82AB; d) Pediatric PICC Kit, kit number UIPP76K;

Z-0826-2024

November 29, 2023

Class II

Product summary

Firm
American Contract Systems, Inc.
Event
Event 93656
Status
Ongoing
Classification
Class II
Quantity
244 units
Official record key
device-enforcement:Z-0826-2024

Official wording

Reason: During an internal investigation, ACS identified that several components were "piggybacked" to ACS trays and subjected to the ACS sterilization process. There is no supporting documentation stating the "piggybacked" components were assessed to determine if they were suitable for exposure to elevated temperatures for an extended period of time and further exposure to sterilization. As a result, the piggybacked components may (1) have a loss/lack of functionality, (2) loss of drug efficacy, if applicable, and (3) may have had higher than specified EO residuals.

Code information: a) UIBP90J, UDI/DI 00191072117038, Lot Numbers: 996231, exp. 1/4/2024; b) UIBP90K, UDI/DI 00191072189356, Lot Numbers: 911231, exp. 7/26/2023; c) UIPO82AB, UDI/DI 00191072172006, Lot Numbers: 727221, exp. 9/30/2023; 680221, exp. 11/16/2023; d) UIPP76K, UDI/DI 00191072142849, Lot Numbers: 637221, exp. 12/29/2023; 976231, exp. 1/24/2024; 898231, exp. 4/12/2024

Distribution pattern: US Nationwide distribution.

Derived failure modes

  • Unknown

    reason.no_named_rule · v1.0.0

    During an internal investigation, ACS identified that several components were "piggybacked" to ACS trays and subjected to the ACS sterilization process. There is no supporting documentation stating the "piggybacked" components were assessed to determine if they were suitable for exposure to elevated temperatures for an extended period of time and further exposure to sterilization. As a result, the piggybacked components may (1) have a loss/lack of functionality, (2) loss of drug efficacy, if applicable, and (3) may have had higher than specified EO residuals.